Effects of supplemented isoenergetic diets varying in cereal fiber and protein content on the bile acid metabolic signature and relation to insulin resistance by Weickert, Martin O. et al.
Weickert et al. Nutrition and Diabetes  (2018) 8:11 
DOI 10.1038/s41387-018-0020-6 Nutrition & Diabetes
ART ICLE Open Ac ce s s
Effects of supplemented isoenergetic diets
varying in cereal ﬁber and protein content
on the bile acid metabolic signature and
relation to insulin resistance
Martin O. Weickert1,2,3, John G. Hattersley4, Ioannis Kyrou1,2,3,5, Ayman M. Arafat6,7, Natalia Rudovich8,
Michael Roden9,10,11, Peter Nowotny11, Christian von Loeffelholz12, Silke Matysik13, Gerd Schmitz13 and
Andreas F. H. Pfeiffer6,7,10
Abstract
Bile acids (BA) are potent metabolic regulators inﬂuenced by diet. We studied effects of isoenergetic increases in the
dietary protein and cereal-ﬁber contents on circulating BA and insulin resistance (IR) in overweight and obese adults.
Randomized controlled nutritional intervention (18 weeks) in 72 non-diabetic participants (overweight/obese: 29/43)
with at least one further metabolic risk factor. Participants were group-matched and allocated to four isoenergetic
supplemented diets: control; high cereal ﬁber (HCF); high-protein (HP); or moderately increased cereal ﬁber and
protein (MIX). Whole-body IR and insulin-mediated suppression of hepatic endogenous glucose production were
measured using euglycaemic–hyperinsulinemic clamps with [6-62H2] glucose infusion. Circulating BA, metabolic
biomarkers, and IR were measured at 0, 6, and 18 weeks. Under isoenergetic conditions, HP-intake worsened IR in
obese participants after 6 weeks (M-value: 3.77 ± 0.58 vs. 3.07 ± 0.44 mg/kg/min, p= 0.038), with partial improvement
back to baseline levels after 18 weeks (3.25 ± 0.45 mg/kg/min, p= 0.089). No deleterious effects of HP-intake on IR
were observed in overweight participants. HCF-diet improved IR in overweight participants after 6 weeks (M-value
4.25 ± 0.35 vs. 4.81 ± 0.31 mg/kg/min, p= 0.016), but did not inﬂuence IR in obese participants. Control and MIX diets
did not inﬂuence IR. HP-induced, but not HCF-induced changes in IR strongly correlated with changes of BA proﬁles.
MIX-diet signiﬁcantly increased most BA at 18 weeks in obese, but not in overweight participants. BA remained
unchanged in controls. Pooled BA concentrations correlated with fasting ﬁbroblast growth factor-19 (FGF-19) plasma
levels (r= 0.37; p= 0.003). Higher milk protein intake was the only signiﬁcant dietary predictor for raised total and
primary BA in regression analyses (total BA, p= 0.017; primary BA, p= 0.011). Combined increased intake of dietary
protein and cereal ﬁbers markedly increased serum BA concentrations in obese, but not in overweight participants.
Possible mechanisms explaining this effect may include compensatory increases of the BA pool in the insulin resistant,
obese state; or defective BA transport.
Introduction
Isoenergetic changes of the dietary macronutrient
composition can have signiﬁcant effects on insulin resis-
tance (IR)1, 2. A high intake of insoluble cereal ﬁbers
(HCF) is associated with a 20–30% reduced risk of
developing type-2 diabetes (T2DM)3, 4. In contrast, high-
protein (HP) intake in sedentary subjects, in the absence
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of sustained weight loss, may increase this risk by the
same magnitude5, 6. Furthermore, HP-intake during
weight loss with a hypocaloric diet appears to eliminate
weight loss-induced improvement of IR in obese sub-
jects7. HP-induced IR could be related to activation of the
mammalian-target-of-rapamycin (mTOR) S6-kinase-1
(S6K1) signaling cascade8–12, with negative effects on IR
possibly being prevented when co-ingesting additional
cereal ﬁbers12 or plant derived (also ﬁber-rich) sources of
protein6, 13, 14, thereby inhibiting the digestion and/or
absorption of dietary protein12.
However, additional mechanisms are likely to be
involved and the signaling potential of bile acids (BA) in
the systemic circulation could play a key role in this
context15. Besides their established role in digestion, BA
are potent regulators of metabolism16–18 that can be
inﬂuenced by diet17, 19–22. BA-uptake by the ileal enter-
ocyte is important for regulation of BA synthesis and gut-
liver signaling15. When transiting through the ileal
enterocyte, BA activate farnesoid-X-nuclear-receptor
(FXR) and increase ﬁbroblast growth-factor-19 tran-
scription (FGF-19; mouse ortholog, FGF-15). Thereafter,
FGF-19 is released from the intestine to inhibit hepatic
BA synthesis23, and regulates aspects of glucose and lipid
metabolism via mainly insulin-like actions24–27. BA-
activation of FXR in hepatocytes increases small-
heterodimer-partner (SHP) expression, leading to
decreased expression of sterol-regulatory-element
binding-protein (SREBP1c) and lipogenesis; and reduced
expression of glucose-6-phosphatase (G6Pase) and
phospoenolpyruvate-carboxykinase (PEPCK), thereby
reducing gluconeogenesis. Thus, changing the levels and/
or composition of circulating BA could have a role for
treating IR and related conditions28–30.
HP-diets may regulate BA-metabolism by modulating
genes involved in energy metabolism and uncoupling17, 19,
21, whereas HCF-rich diets inﬂuence both BA binding and
BA reabsorption from the gut via their lignin/cellulose
contents20, 22, 31, 32. Notably, diet-induced metabolic effects
appear to be different between obese, more insulin-resistant
and non-obese, less insulin-resistant subjects33, 34. To date,
the effects of isoenergetic, HP and/or HCF supplemented
diets on circulating BA and their relation to adiposity and
changes in IR have not been investigated in controlled
human interventions. To increase power, we additionally
investigated potential differences between overweight and
obese subjects in BA signatures and associated metabolic
markers in the pooled cohort (all 4 dietary groups
combined).
Subjects and methods
Study population
This study presents additional analyses from the Pro-
tein, Fiber and Metabolic Syndrome (ProFiMet) data set
(clinicaltrials.gov, NCT00579657), described in our core
publication12. The Ethics Committee of the University of
Potsdam approved the study (BMBF-FKZ-0313826). All
participants provided written informed consent. Herein,
we present results of a sub-group of 72 participants from
the ProFiMet study who successfully had completed the
18 weeks dietary intervention (i.e., who had attended all
study days, maintained their body weight, had complete
data from dietary monitoring, did not change their exer-
cise habits and did not take drugs known to affect IR (i.e.,
steroids, antibiotics, or acetylic salicylic acid35)); and had
complete measurements of circulating BA (weeks 0, 6,
and 18). All participants: (i) were Caucasian; (ii) were
either overweight (BMI ≥ 25 but <30 kg/m2; n= 29) or
obese (BMI ≥ 30 kg/m2; n= 43); (iii) had waist cir-
cumference >80 cm in females and >94 cm in males; and
(iv) had at least one more feature of the metabolic syn-
drome (but no diabetes) according to the International
Diabetes Federation deﬁnition/criteria36. Participants
underwent an oral glucose tolerance test prior to the
intervention. Baseline characteristics in the four dietary
groups were comparable (all p > 0.1; Table 1). Char-
acteristics when comparing overweight and obese parti-
cipants from the pooled dietary groups are presented in
Table 2.
Dietary intervention
Details of this dietary intervention have been pub-
lished12. In brief, participants were group-matched
according to age, sex, waist circumference, BMI and
drug intake and randomly allocated to one of four mod-
erately fat reduced (30% of energy content) diets, varying
in protein and cereal ﬁber content (control (C); high
cereal ﬁber (HCF); high protein (HP); or moderately
increased cereal ﬁber and protein (MIX)). (Table 1). All
diets were isoenergetic and based on assumed healthy
foods (details are provided in supplementary materials,
including Supplementary Table 1). In the HP-group, high-
fat animal-protein sources were restricted. Participants in
all 4 dietary groups received tailored supplements (4 lots,
containing 63 portions each at weeks 0, 3, 6, and 12,
respectively) for twice daily consumption throughout the
18 weeks intervention. A selection of drinking powders in
ﬁve different ﬂavors, together with a purpose-made sha-
ker; and a baking mix for the preparation of pancakes was
provided in each dietary group. Supplements were dis-
solved in low fat (1.5%) milk, 200 mL per portion when
using drinking powders; or 120mL when using baking
mixes, as per the participant’s preference but ideally in a
1:1 ratio. Supplements provided to the control group were
based on a low-ﬁber grain mixture, which also served as
carrier for the cereal ﬁber and protein-enriched supple-
ments in the other intervention groups. The HCF dietary
supplements were enriched with 2 × 15-g insoluble cereal
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ﬁber extracts from oat hulls; the HP dietary supplements
contained 2 × 29-g isolates from whey and pea proteins,
and the supplements provided to the mix groups con-
tained 2 × 8-g cereal ﬁber extracts from oat hulls and 2 ×
19-g protein isolates from whey and peas. During the ﬁrst
6 weeks, participants weighed all foods and provided
detailed information on processing, cooking, and brand
names. According to daily food protocols during the ﬁrst
6 weeks, the achieved percent intakes of protein and
carbohydrates and intake of cereal ﬁber per day were 17%,
52%, and 14 g in controls; 17%, 52%, and 43 g in HCF;
28%, 43%, and 13 g in HP; and 23%, 44%, and 26 g in MIX.
Differences in protein intake between groups were
balanced by modulating carbohydrate intake. Fat contents
were comparable between diets (total fat intake (g), p >
0.45; percent fat intake, p > 0.14 at all study days). Bio-
markers for protein intake (urine ratio nitrogen/creati-
nine; fecal isovaleric acid) and fermentable ﬁber intake
(fecal butyrate; breath hydrogen) were used to monitor
dietary adherence12.
Body composition and liver fat content
Anthropometric measurements were performed by
trained staff, using standard methods. Body fat content
was assessed using 1.5T magnetic resonance imaging
(Magnetom Avanto, Siemens Healthcare, Erlangen,
Germany)12. Proton magnetic resonance spectroscopy
(1H-MRS) was utilized to assess hepatic lipid
content12, 37.
Whole-body insulin resistance and insulin-induced
suppression of hepatic glucose production
Euglycemic–hyperinsulinemic clamps (40 mU/kg/min)
were performed in the overnight fasted state at weeks 0, 6,
and 18 (n= 15–20 participants/group and study day) to
assess whole-body IR (expressed as M-value). Tracer
experiments were performed in a matched subset of
participants (n= 9–11 participants/group and study day),
to measure endogenous (hepatic) glucose production
(EGP) and EGP-suppression by insulin infusion. Hepatic
IR (HEP-IR) was estimated as EGP x fasting plasma
insulin (FPI)37.
Sample preparation
Blood samples were drawn in timed intervals at baseline
and throughout the clamp experiments, following 12-h
overnight fasting. Samples were immediately chilled and
centrifuged, and the supernatant ﬂuid was aliquoted and
stored at −80 °C until analyzed.
Bile acid (BA) measurement
Plasma BA were analyzed using liquid chromatography-
tandem mass spectrometry (LC–MS/MS), as described38.
The LC–MS/MS system consisted of an API-4000-Ta
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QTrap (AB-Sciex, Darmstadt, Germany) coupled with
electrospray ionization interface operated in the multiple-
reaction monitoring positive ion-mode. Chromatographic
separation was performed on Agilent-1200 HPLC system
(Agilent, Waldbronn, Germany) with a Kinetex C18 col-
umn (50 × 2.1 mm, 2.6 µm; Phenomenex). Details are
provided in the supplementary materials. The categor-
ization of key BA is summarized in Supplementary
Table 2.
Measurement of butyric acid in fecal samples
Assessment of fecal butyric acid deﬁciency was used as
an indirect indicator of impaired intestinal barrier func-
tion39. Details are provided in the supplementary
materials.
Other biomarkers
FGF-19 was measured by enzyme-linked immunosor-
bent assay (R&D Systems, Minneapolis, MN). All other
biomarkers in blood and hydrogen breath tests were
measured as detailed previously12.
Study sample size justiﬁcation
Power calculation for the detection of diet-induced
changes in IR was initially based on 26 participants for
each dietary group and an assumed dropout rate of 30%
per group12. Signiﬁcant diet-induced changes in IR were
also observed in the herein presented sub-cohort of par-
ticipants with available complete data on BA measure-
ments. Further, a recent study by Haeusler et al.40 showed
increased BA synthesis in human obesity, with a sample
size of 32 obese and 11 non-obese non-diabetic Caucasian
adults. Therefore, a sample size of 43 obese and 29 non-
obese participants in our study was assumed to be
sufﬁcient.
Statistical analyses
Data are presented as means ± standard error (SEM).
Signiﬁcance was deﬁned as p < 0.05. Analysis of variance
(ANOVA) and t-tests were used to compare study sub-
groups. Two-way ANOVA was additionally used, with
factors of obesity and dietary group, to investigate changes
in BA concentrations. Repeated measures ANOVA, with
dietary group as the factor, was used for longitudinal
comparison between dietary groups and time, with cor-
rections for sphericity applied. Log-transforms were
applied for not normally distributed data. Forward step-
wise regression, Pearson’s correlation and partial corre-
lations (adjusted for BMI and age41, with gender showing
no inﬂuence in our analyses) were used to test relation-
ships between BA concentrations and measures of IR.
Analyses were performed using SPSS version 24 (SPSS
Inc., Chicago, IL).
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Results
Diet-induced changes on insulin resistance
At baseline, IR was comparable between dietary groups
(Table 1). Both whole-body IR (M-value) and EGP dif-
fered between dietary groups at 6 weeks (M-value, p=
0.048; EGP, p= 0.005), driven by opposite changes in the
HP and HCF groups:M-value improved in the HCF group
at 6 weeks (3.80 ± 0.39 (week-0) vs. 4.15 ± 0.34 (week-6)
mg/kg/min; p= 0.037), but was not different from base-
line at 18 weeks (p= 0.11). In the HP group, M-value
worsened after 6 weeks (3.93 ± 0.41 (week-0) vs. 3.31 ±
0.32 (week-6) mg/kg/min; p= 0.011), but was not differ-
ent from baseline after 18 weeks (p= 0.46). M-value did
not change in control and MIX, neither after 6 nor
18 weeks. Estimated hepatic IR (expressed as HEP-IR=
EGP × FPI)37 was unaffected by the dietary intervention
(p > 0.65).
Diet-induced changes in IR when comparing overweight
vs. obese participants
At baseline, IR was signiﬁcantly different between
overweight and obese individuals (Table 2), as expected.
When consuming HCF for 6 weeks, whole-body IR
improved in overweight (M-value: 4.25 ± 0.35 (week-0) vs.
4.81 ± 0.31 (week-6) mg/kg/min; p= 0.016), but not in
obese participants (p= 0.29). In contrast, HP-diet for
6 weeks worsened IR in obese (M-value: 3.77 ± 0.58
(week-0) vs. 3.07 ± 0.44 (week-6) mg/kg/min; p= 0.038),
but not in overweight participants (p= 0.18). Control and
MIX diets did not inﬂuence IR, neither in obese nor in
overweight participants (all p > 0.42).
After 18 weeks, improved IR in overweight participants
in the HCF group (M-value: 4.25 ± 0.35 (week-0) vs. 5.12
± 0.47 (week-18) mg/kg/min; p= 0.055) and worsened IR
in obese participants in the HP-group (M-value: 3.77 ±
0.58 (week-0) vs. 3.25 ± 0.45 (week-18) mg/kg/min; p=
0.089) tended to be maintained, but statistical signiﬁcance
was not reached. Control and MIX diets did not inﬂuence
IR, neither in obese nor in overweight participants (all p >
0.29).
Dietary factors inﬂuencing BA-circulating proﬁles
At baseline, BA were comparable between dietary
groups (Table 1). Absolute BA in overweight and obese
participants combined were not inﬂuenced by the
respective diets. However, two-way repeated measures
ANOVA (weeks 0, 6 and 18; obese vs. overweight; dietary
intervention) revealed differences in the summations of
the secondary, tertiary, 12-alpha and unconjugated BA
over the intervention periods (∑secondary BA: p < 0.0001;
∑tertiary BA: p= 0.02; ∑12-α: p= 0.03; unconjugated BA:
p= 0.05, respectively). After correction for the baseline,
changes in BA between overweight and obese participants
were not signiﬁcant after 6 weeks, but marked and
statistically signiﬁcant at 18 weeks (Fig. 1). This effect was
mainly driven by signiﬁcant increases of BA in obese
participants consuming MIX, whereas no signiﬁcant
changes between overweight and obese participants were
observed in the control, HCF, and HP-groups (Fig. 2).
Percent protein intake between obese and overweight
participants in the respective dietary groups was com-
parable (obese vs. overweight: control: 21.1 ± 0.7% vs. 20.2
± 0.8%, p= 0.38; HCF: 17.9 ± 0.9 vs. 15.9 ± 0.4%, p= 0.08;
HP: 26.7 ± 0.4 vs. 26.4 ± 1.4%, p= 0.86; MIX: 21.4 ± 1.7 vs.
21.8 ± 0.6%, p= 0.64). After 18 weeks, in the entire
cohort, higher milk protein intake was the only dietary
predictor for raised total BA and primary BA in stepwise
regression analyses (p= 0.017 and p= 0.011,
Fig. 1 Comparison of bile acids (BA) circulating concentrations
between obese (n= 43; white bars) and overweight (n= 29;
black bars) participants in the pooled cohort, irrespective of the
dietary groups. The graph shows changes relative to the baseline
values (week 0) after a 6 weeks and b 18 weeks of dietary intervention.
*Statistically signiﬁcant at alpha < 0.05. ∑All: sum of all BA; ∑Prim: sum
of primary BA; ∑Sec: sum of secondary BA; ∑Tert: sum of tertiary BA; 12-
α: 12-α hydroxyl BA; non 12-α: non 12-α hydroxylated BA; 12-α/non
12-α: ratio of 12-α hydroxyl BA to non 12-α hydroxylated BA; Conj:
conjugated BA; Unconj: unconjugated BA; Conj/Unconj: ratio of
conjugated to unconjugated BA
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Fig. 2 (See legend on next page)
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respectively). None of the other protein sources (red meat,
ﬁsh, poultry, eggs or legumes) showed signiﬁcant inﬂu-
ences (all p > 0.18). Milk protein intake explained 7% of
changes in total BA and 8% of changes in primary BA.
Fecal butyrate
Fecal butyrate was not different between the dietary
groups, neither at baseline nor throughout the interven-
tion (p > 0.57). However, there was a signiﬁcant difference
between overweight and obese participants, both at
baseline (p= 0.019) and after 18 weeks, when correcting
for the baseline (p= 0.009). In sub-group analyses, fecal
butyrate decreased between 6 and 18 weeks of HP-diet in
obese participants only (baseline: 17.2 ± 2.7 mmol/L;
week-6: 18.1 ± 2.3 mmol/L, week 18: 11.8 ± 1.5 mmol/L, p
= 0.048) and did not signiﬁcantly change in the remaining
dietary groups.
Circulating FGF-19
Fasting FGF-19 plasma levels were not different
between dietary groups, neither at baseline nor during the
dietary intervention. In the pooled cohort (all 4 dietary
groups combined), FGF-19 tended to be higher in obese
vs. overweight individuals, both at baseline and through-
out the dietary intervention (week-0: 116.6 ± 12.3 vs.
105.54 ± 9.21 pg/mL; week-6: 112.5 ± 11.8 vs. 99.4 ± 8.9
pg/mL; and week-18: 122.6 ± 9.7 vs. 98.0 ± 12.2 pg/mL),
but statistical signiﬁcance was not reached (all p > 0.052).
When correcting for the baseline, there was a signiﬁcant
effect of the dietary intervention over time for FGF-19
(F(1.54,103.54)= 3.47, p= 0.047), but no signiﬁcant inter-
action between time and the obese/overweight categor-
ization. A change in fasting FGF-19 plasma levels
explained 7% of the changes in total BA in regression
analyses (p= 0.031).
Correlation analyses
Fecal butyrate correlation analyses
In uncorrected correlation analyses, no correlation
between fecal butyrate and breath hydrogen was observed
at baseline (r=−0.07; p= 0.54), but became signiﬁcant
after 6 weeks (r= 0.25; p= 0.039) and disappeared again
after 18 weeks (r= 0.16; p= 0.22). At baseline, fecal
butyrate correlated with both IHL (r= 0.26, p= 0.046)
and M-value (r= 0.35, p= 0.005). Correlations of fecal
butyrate with IHL remained signiﬁcant after 6 weeks (r=
0.28, p= 0.023) and 18 weeks (r= 0.25, p= 0.048), but
correlations with M-value disappeared (6 weeks: r=
−0.08, p= 0.53; 18 weeks: r=−0.08, p= 0.53). There
were no signiﬁcant correlations of fecal butyrate and BA
or FGF-19. After adjusting for age and BMI, no signiﬁcant
correlations of fecal butyrate and above parameters were
observed.
BA partial correlations in the pooled cohort (all 4 dietary
groups and overweight and obese participants combined)
Partial correlation coefﬁcients (adjusted for age and
BMI) in the pooled cohort between the summations of
different BA subsets and IR measures, intrahepatic lipid
content (IHL) and FGF-19 are presented in Table 3.
At baseline, only conjugated BA were positively corre-
lated with HOMA-IR (r= 0.24, p= 0.05) and HEP-IR (r
= 0.24, p= 0.05), but not with FPI and M-value.
At week-6, total, primary, tertiarym and conjugated BA
correlated signiﬁcantly with all IR measures. At week-18,
most of the observed signiﬁcant correlations at week-6
remained signiﬁcant and correlation coefﬁcients were
strengthening (Table 3). In addition, correlations of 12-
alpha BA and the ratio of conjugated/unconjugated BA
with HOMA-IR and FPI became signiﬁcant. Apart from a
positive correlation of IHL with tertiary BA after 6 weeks
(IHL: ∑Tert: r= 0.26, p < 0.001), no relation of IHL with
total BA or BA subsets was observed. No signiﬁcant
correlations were noted between FGF-19 plasma levels
and IR measures (weeks 0, 6 and 18).
Partial correlations of BA with IR in the HP and HCF dietary
groups (overweight and obese subjects combined)
Signiﬁcant diet-induced changes of IR were observed in
the HP- and HCF groups, but not in control and MIX.
Thus, additional correlation analyses were restricted to
HP and HCF. In the HP-group, there were no signiﬁcant
correlations between BA and IR measures at baseline, but
there were numerous strong and statistically signiﬁcant
correlations of these measures after 6 and 18 weeks of
HP-intake (supplementary materials). In the HCF group,
no signiﬁcant correlations were observed, neither at
baseline nor after 18 weeks. However, partial correlations
(see ﬁgure on previous page)
Fig. 2 Comparison of circulating bile acids (BA) concentrations, relative to baseline value at week 0, after 6 and 18 weeks between obese
(ob) and overweight (ow) subjects in the 4 diet groups : a Control at 6 weeks (ow/ob: n= 10/10). b Control at 18 weeks (ow/ob: n= 10/10). c
High cereal ﬁber (HCF) at 6 weeks (ow/ob: n= 5/10). d HCF at 18 weeks (ow/ob: n= 5/10). e High protein (HP) at 6 weeks (ow/ob: n= 6/12); f HP at
18 weeks (ow/ob: n= 6/12). g Mixed-diet (MIX) group at 6 weeks (ow/ob: n= 8/11). h MIX at 18 weeks (ow/ob: n= 8/11). Black bars: overweight;
white bars: obese. *Statistically signiﬁcant at alpha < 0.05. ∑All: sum of all BA; ∑Prim: sum of primary BA; ∑Sec: sum of secondary BA; ∑Tert: sum of
tertiary BA; 12-α: 12-α hydroxyl BA; non 12-α: non 12-α hydroxylated BA; 12-α/non 12-α: ratio of 12-α hydroxyl BA to non 12-α hydroxylated BA; Conj:
conjugated BA; Unconj: unconjugated BA; Conj/Unconj: ratio of conjugated to unconjugated BA
Weickert et al. Nutrition and Diabetes  (2018) 8:11 Page 9 of 15
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Table 3 Partial correlation heat matrix at 0, 6, and 18 weeks between different bile acids (BA) and insulin resistance (IR)
measures, intrahepatic lipid content (IHL) and ﬁbroblast growth factor-19 (FGF-19) plasma levels, when corrected for age
and body mass index (BMI), in the pooled cohort (n= 72; all four dietary groups and overweight and obese participants
combined)
Bold font denotes signiﬁcant correlations at α= 0.05; strength of color indicates the magnitude of the Pearson’s correlation value (r); red indicates positive and blue
indicates negative correlations
∑All sum of all bile acids (BA) pooled, ∑Prim sum of primary BA, ∑Sec sum of secondary BA, ∑Tert sum of tertiary BA, 12-α 12-α hydroxyl BA, non 12-α non 12-α
hydroxylated BA, 12-α/non 12-α= ratio of 12-α hydroxyl BA to non 12-α hydroxylated BA, Conj conjugated BA, Unconj unconjugated BA, Conj/Unconj ratio of
conjugated to unconjugated BA, HOMA-IR homeostasis model assessment for insulin resistance, HEP-IR hepatic insulin resistance, FPI fasting plasma insulin, M-value
insulin-mediated glucose uptake as a measurement of whole-body insulin sensitivity, IHL intrahepatic fat content, FGF-19 ﬁbroblast growth factor-19
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of BA with M-value were signiﬁcant for several BA sub-
sets after 6 weeks (supplementary materials).
Partial correlations between BA and FGF-19
Baseline fasting FGF-19 was positively correlated with
most of the BA summations/subsets and negatively cor-
related with the conjugated/unconjugated BA ratio
(Table 3). At week-6, correlations of 12-α, 12-α/non 12-α,
and unconjugated BA remained signiﬁcant (all p < 0.05),
whereas at week-18 we noted a return to the baseline
pattern (Table 3).
Figure 3 presents the partial correlation plots of FGF-19
with the sum of all BA and 12-α BA at week-18 in the
pooled cohort (all four dietary groups combined) (Fig. 3a,
b); and partial correlation plots of FGF-19 and the sum of
all BAs in each dietary group (Fig. 3c–f). FGF-19 sig-
niﬁcantly correlated with all BA and 12-α BA in the
pooled cohort and in the control and MIX dietary groups,
with a similar trend in the HP-diet group. No signiﬁcant
correlation of FGF-19 with BA was observed in the HCF
group (Fig. 3d).
Discussion
Under weight-maintaining conditions, HCF-diets
improve and plant based HP-diets worsen IR in subjects
at risk of developing T2DM after short-term (6 weeks)
exposure, with reversal back to baseline levels after more
prolonged (18 weeks) intervention12. Herein, we expand
Fig. 3 Partial correlation plots for circulating bile acids (BA) vs. ﬁbroblast growth factor-19 (FGF-19) plasma concentrations, corrected for
age and body mass index (BMI), measured after 18 weeks of dietary intervention. a All study subjects: all BA pooled vs. FGF-19 (n= 68). b All
study subjects: 12-alpha BA vs. FGF-19 (n= 68). c Control group only: all pooled BA vs. FGF-19 (n= 18). d High cereal ﬁber group (HCF) only: all
pooled BA vs. FGF-19 (n= 15). e High protein (HP) group only: all pooled BA vs. FGF-19 (n= 17). f Mixed-diet (MIX) group only: all pooled BA vs. FGF-
19 (n= 18). R correlation coefﬁcient
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on our previous ﬁndings by showing (i) signiﬁcant dif-
ferences of these diets on IR depending on the degree of
adiposity; (ii) effects of these diets on the BA metabolic
signatures and their relation to measures of IR; and (iii)
investigating the relation of BA signatures and IR with
FGF-19, an ileum-derived enterokine which is post-
prandially induced by BA and has established effects on
BA synthesis and glucose metabolism25, 42, 43.
Isoenergetic HCF vs. HP intake over 6 weeks changed
IR in opposite directions, with signiﬁcantly improved IR
in overweight, but not in obese subjects in the HCF group;
and signiﬁcantly deteriorated IR in obese, but not in
overweight subjects in the HP-group. Effects of the pre-
scribed diets on IR weakened after more prolonged
(18 weeks) intervention, which could be related to some
drop in adherence especially to the HP-diet12, or adaptive
processes. When adding cereal ﬁbers to HP-intake, wor-
sening of IR in obese participants was prevented and
associated with markedly and signiﬁcantly increased
serum concentrations of most BA, whereas BA remained
unchanged in overweight, less insulin-resistant partici-
pants. Potential mechanisms explaining these effects may
include compensatory increases of the BA pool in the
insulin-resistant state, including increased synthesis of
12α-hydroxylated BA;40 possibly leading to reduced lipo-
genesis and inhibition of gluconeogenesis in the liver via
BA induced activation of FXR15. Blocking intestinal
absorption of BA also increases the ﬂux of BA into the
colon and can increase the plasma membrane-bound G
protein-coupled receptor TGR5 [TGR5(Gpbar-1)]-medi-
ated release of glucagon like peptide-1, thereby improving
IR15, 44, 45. However, defective BA transport in the insulin
resistant, obese state has been also proposed40 and the
exact mechanisms leading to different responses of BA
depending on both IR and dietary factors remain to be
further explored.
The observed interrelations of the BA signature in our
study with both speciﬁc dietary contents and the degree of
adiposity and IR adds to the complexity of the inter-
pretation of recent observations of others, who have
shown strong associations of increased circulating BA
with IR in both diabetic and non-diabetic populations;41,
46–48 and relations between circulating BA and liver fat
content49, with the latter known to strongly inﬂuence
IR50. In rodents, consumption of a HP-diet increases
circulating BA, associated with improvement in metabolic
markers51, 52. Moreover, in a short-term crossover inter-
vention in 10 healthy normal weight men on a combined
high-fat plus HP-diet, circulating BA signiﬁcantly
increased, compared to ingestion of high-fat diet alone19,
whereas in our study fat consumption was moderately
restricted. Further, euglycaemic hyperinsulinaemic clamp
studies have shown marked, near 50% suppression of
serum BA levels in lean subjects, but impairment of the
ability of insulin to decrease BA in obese, insulin-resistant
subjects40. However, in our study, only HP-induced (but
not HCF-induced) changes in IR correlated with sig-
niﬁcant changes in BA proﬁles. Further, HP diet-induced
worsening of IR in our obese participants only tended to
increase circulating BA, whereas effects were striking
when adding cereal ﬁber to the HP-diet (MIX-diet). These
ﬁndings may indicate that a combination of stimulated
BA production by increasing the dietary protein content
and modulation of BA absorption via the cereal ﬁber
content may be needed to unmask altered BA metabolic
signatures in the obese, insulin-resistant state. Indeed, our
ﬁnding of major dietary effects on the BA signature with
combined HP and cereal ﬁber intake only is indirectly
supported by early observations from Cummings et al.20,
who had observed, in lean subjects, doubling of BA fecal
excretion with combined HP and cereal ﬁber intake, but
no effect when increasing these dietary components iso-
lated. Measurements of fecal BA excretion were not
included in our study. However, our ﬁnding that plasma
BA including secondary BA doubled with combined HCF
and HP-intake only (but not when increasing cereal ﬁber
or dietary protein contents isolated) and that this effect
was apparent only in obese (more insulin-resistant) par-
ticipants may suggest increased colonic reabsorption of
BA in the obese, IR state, leading to signiﬁcantly increased
plasma BA. Indeed, intestinal permeability is increased in
obese, more insulin-resistant patients with hepatic stea-
tosis, compared with obese patients without increased
liver fat content39, indicating that IR rather than changes
in body weight per se could be a key factor in this context.
The oat-hull derived cereal ﬁber supplements used in our
studies were neither fermented in vivo, as indicated by
absence of changes in hydrogen breath tests over
18 weeks of dietary intervention12, nor in vitro53. There-
fore, signiﬁcant differences in fecal butyrate concentra-
tions between overweight and obese participants in our
study may support altered intestinal permeability in the
insulin-resistant state, which could partly explain the
observed different diet-induced changes in BA signatures
between overweight and obese subjects.
Another ﬁnding of the present study was that diet-
induced changes in circulating FGF-19 independently
associated some of the changes in BA, although this effect
was weak. FGF-19 signiﬁcantly increases in T2DM
patients after bariatric surgical procedures, associated
with metabolic improvement54–57. This appears related to
the direct ﬂow of “digestate”-free BA into the ileum after
such bariatric operations, which may be more bioactive
and induce greater local stimulation of FGF-1954, 57.
Similarly, it may be hypothesized that when adding cereal
ﬁber to a HP-diet, FGF-19 and BA secretion/levels may be
inﬂuenced by ﬁber-related interference of the digestion
and/or absorption of dietary protein12, 58, 59. Indeed, FGF-
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19 signiﬁcantly correlated with total BA in the control and
MIX-diet groups, with a similar trend in the HP-group,
whereas this correlation was lost in the HCF group. This
is also in line with our previous ﬁnding of diminished
correlations of IR markers with circulating amino acid
metabolic signatures in the HCF group only60.
Finally, among the various protein sources in this study,
only higher milk protein intake was a signiﬁcant dietary
predictor for changes in BA. Of note, non-fat milk has
been shown to stimulate FGF-19 expression in vitro,
whereas whole-milk had no such effect57, possibly related
to the higher protein contents in non-fat milk. In our
study, all participants had increased their intake of low-fat
milk throughout the 18-week intervention, related to the
fact that participants in all four dietary groups were
instructed to dissolve their twice daily consumed dietary
supplements in low-fat milk. This measure may have
diminished differences between dietary groups regarding
FGF-19 and BA levels.
Strengths and limitations
Our study has multiple strengths, which include the
assessment of the impact of the applied diets on circu-
lating BA proﬁles in a randomized, controlled interven-
tion with tightly matched groups; use of dietary
supplements in all groups to enhance discrimination
between diets; strict monitoring of the respective diets
including the use of biomarkers of adherence; and use of
predeﬁned exclusion criteria for maintaining a stable body
weight during the intervention, to avoid potential con-
founding effects of weight ﬂuctuation on the study out-
comes. Furthermore, our protocol employed state-of-the-
art methods for the assessment of the principal study
outcomes.
However, certain limitations should be acknowledged.
The lack of a study group of participants with BMI in the
normal range could be viewed as a limitation of the pre-
sent work, as well as the fact that the number of partici-
pants in sub-group analyses was relatively small. However,
our protocol allowed us to compare the dietary effects on
BA proﬁles between obese and overweight adults, with the
latter constituting a patient population that has been less
studied in this context. Further, measurements of fecal BA
excretion and the BA precursor serum 7α-hydroxy-4-
cholesten-3-one (C4) were not available and we were also
not able to explore the potential effects of the applied
dietary interventions on postprandial circulating BA
proﬁles, related to the design of our study.
Conclusion
Our study shows that, under isoenergetic conditions,
differences in the protein and cereal ﬁber contents of a
diet can lead to signiﬁcant changes in both IR and the BA
metabolic signatures. These effects appear to be
inﬂuenced by the degree of IR and adiposity of the
respective subjects. Hence, our ﬁndings add to existing
knowledge and shed light on the complex relationship
between BA, IR, and diet manipulations.
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